KPTI logo

KPTI
Karyopharm Therapeutics Inc

7,926
Mkt Cap
$195.23M
Volume
267,905.00
52W High
$10.99
52W Low
$3.65
PE Ratio
-0.52
KPTI Fundamentals
Price
$8.66
Prev Close
$8.75
Open
$8.77
50D MA
$8.15
Beta
1.08
Avg. Volume
1.73M
EPS (Annual)
-$17.93
P/B
-0.54
Rev/Employee
$640,644.74
$250.34
Loading...
Loading...
News
all
press releases
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for...
PR Newswire·4d ago
News Placeholder
More News
News Placeholder
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving Average - What's Next?
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above Fifty Day Moving Average - Should You Sell...
MarketBeat·5d ago
News Placeholder
Nuclear Stocks Worth Watching - April 13th
Oklo, NuScale Power, BWX Technologies, Centrus Energy, Nano Nuclear Energy, HCM II Acquisition, and Karyopharm Therapeutics are the seven Nuclear stocks to watch today, according to MarketBeat's...
MarketBeat·12d ago
News Placeholder
Best Nuclear Stocks To Follow Today - April 9th
Oklo, BWX Technologies, NuScale Power, Centrus Energy, Nano Nuclear Energy, HCM II Acquisition, and Karyopharm Therapeutics are the seven Nuclear stocks to watch today, according to MarketBeat's stock screener tool. "Nuclear stocks" is informal slang among investors for equities that are extremely...
MarketBeat·16d ago
News Placeholder
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock...
MarketBeat·23d ago
News Placeholder
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling...
MarketBeat·25d ago
News Placeholder
Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)
Piper Sandler reiterated an "overweight" rating and set a $8.00 target price (down from $12.00) on shares of Karyopharm Therapeutics in a research note on Monday...
MarketBeat·26d ago
News Placeholder
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·29d ago
News Placeholder
HC Wainwright Has Optimistic Outlook of KPTI Q1 Earnings
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 EPS estimates for Karyopharm Therapeutics in a note issued to investors on Wednesday, March...
MarketBeat·29d ago
News Placeholder
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.
Zacks·1mo ago
<
1
2
...
>

Latest KPTI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.